Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis

Oncogene

Volumn 24, Issue 55, 2005, Pages 8114-8127

  Vega, Mario I ^a,b   Huerta Yepez, Sara ^a,b   Jazirehi, Ali R ^a   Garban, Hermes ^a,c   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fas; NF B; Non Hodgkin's lymphoma; Sensitization; YY1

Indexed keywords

3 [(4 TERT BUTYL PHENYL)SULFONYL] 2 PROPENENITRILE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 HYDROXYTAMOXIFEN; BAY 11 7085; CD20 ANTIBODY; CHIMERIC ANTIBODY; ESTROGEN RECEPTOR; FAS ANTIBODY; FAS LIGAND; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; RITUXIMAB; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YIN YANG 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTRACELLULAR SPACE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; TRANSCRIPTION, GENETIC;

EID: 28744442248     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208954     Document Type: Article

References (31)

1. Alas S, Emmanouilides C and Bonavida B. (2001). Clin. Cancer Res., 7, 709-723.
2. Barnhart BC, Alappat EC and Peter ME. (2003). Semin. Immunol., 15, 185-193.
3. Berenbaum MC. (1981). Adv. Cancer Res., 35, 269-335.
4. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D and Reed JC. (2002). Blood, 99, 1038-1043.
5. Canfield SM and Morrison SL. (1991). J. Exp. Med., 173, 1483-1491.
6. Cragg MS and Glennie MJ. (2004). Blood, 103, 2738-2743.
7. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB and Johnson P. (1995). J. Biol. Chem., 270, 22632-22638.
8. Emmanouilides C, Territo M, Menco H, Patel R and Rosen P. (2003). Hematol. Oncol., 21, 99-108.
9. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman Jr CA and Miller TP. (1993). N. Engl. J. Med., 328, 1002-1006.
10. Freedman AS and Nadler LM. (1991). Hematol. Oncol. Clin. N. Am., 5, 871-889.
11. Garban HJ and Bonavida B. (2001). J. Immunol., 167, 75-81.
12. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A and Introna M. (2001). Blood, 98, 3383-3389.
13. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA and Connelly PA. (1996). J. Biol. Chem., 271, 695-701.
14. Hongo F, Garban H, Huerta-Yepez S, Vega MI, Jazirehi A, Mizutani Y and Bonavida B. (2004). 95th Annual Meeting of American Association for Cancer Research Proceedings. Orlando, FL, Vol. 45, p. 105 (abstract #4356).
15. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G and Bonavida B. (2004). Oncogene, 23, 4993-5003.
16. Iwasaki S, Iguchi M, Watanabe K, Hoshino R, Tsujimoto M and Kohno M. (1999). J. Biol. Chem., 274, 26503-26510.
17. Iida M, Towatari M, Nakao A, Iida H, Kiyoi H, Nakano Y, Tanimoto M, Saito H and Naoe T. (1999). Leukemia, 13, 585-589.
18. Jazirehi AR and Bonavida B. (2005). Oncogene, 24, 2121-2143.
19. Jazirehi AR, Gan XH, De Vos S, Emmanouilides C and Bonavida B. (2003). Mol. Cancer Ther., 2, 1183-1193.
20. Jazirehi AR, Huerta-Yepez S, Cheng G and Bonavida B. (2005). Cancer Res., 65, 264-276.
21. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L and Bonavida B. (2004). Cancer Res., 64, 7117-7126.
22. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL and Taylor RP. (2003). Blood, 101, 1071-1079.
23. Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G. (1999). Proc. Natl. Acad. Sci. USA, 96, 9136-9141.
24. Li-Weber M and Krammer PH. (2003). Semin. Immunol., 15, 145-157.
25. Martin-Blanco E. (2000). Bioessays, 22, 637-645.
26. Mori N, Fujii M, Cheng G, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M and Yamamoto N. (2001). Virus Genes, 22, 279-287.
27. Ogasawara T, Yasuyama M and Kawauchi K. (2003). Int. J. Hematol., 77, 364-370.
28. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T and Gerritsen ME. (1997). J. Biol. Chem., 272, 21096-21103.
29. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR. (1994). Blood, 83, 435-445.
30. Shan D, Ledbetter JA and Press OW. (2000). Cancer Immunol. Immunother., 48, 673-683.
31. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C and Bonavida B. (2004). Oncogene, 23, 3530-3540.